ATE338043T1 - 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten - Google Patents

5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten

Info

Publication number
ATE338043T1
ATE338043T1 AT02777254T AT02777254T ATE338043T1 AT E338043 T1 ATE338043 T1 AT E338043T1 AT 02777254 T AT02777254 T AT 02777254T AT 02777254 T AT02777254 T AT 02777254T AT E338043 T1 ATE338043 T1 AT E338043T1
Authority
AT
Austria
Prior art keywords
aöpyridine
methoxy
aryl
derivatives
receptor antagonists
Prior art date
Application number
AT02777254T
Other languages
German (de)
English (en)
Inventor
Matthias Heinrich Nettekoven
Sebastien Schmitt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE338043T1 publication Critical patent/ATE338043T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02777254T 2001-10-08 2002-09-28 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten ATE338043T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01123949 2001-10-08

Publications (1)

Publication Number Publication Date
ATE338043T1 true ATE338043T1 (de) 2006-09-15

Family

ID=8178877

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02777254T ATE338043T1 (de) 2001-10-08 2002-09-28 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten

Country Status (16)

Country Link
US (1) US6693116B2 (enExample)
EP (1) EP1436292B1 (enExample)
JP (1) JP4101756B2 (enExample)
KR (1) KR100604407B1 (enExample)
CN (1) CN1254475C (enExample)
AR (1) AR036735A1 (enExample)
AT (1) ATE338043T1 (enExample)
AU (1) AU2002338827B2 (enExample)
BR (1) BR0213177A (enExample)
CA (1) CA2462801A1 (enExample)
DE (1) DE60214408T2 (enExample)
ES (1) ES2269772T3 (enExample)
MX (1) MXPA04003278A (enExample)
PL (1) PL370565A1 (enExample)
RU (1) RU2298009C2 (enExample)
WO (1) WO2003031445A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1830978B (zh) * 2005-03-07 2010-06-16 中国人民解放军军事医学科学院毒物药物研究所 吡唑并[4,3-c]喹啉-3-酮化合物、其制备方法及其应用
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2288260A4 (en) * 2008-06-20 2013-10-23 Genentech Inc TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
EP2296475A4 (en) 2008-06-20 2014-03-05 Genentech Inc TRIAZOLOPYRIDINE COMPOUNDS JAK KINASE INHIBITORS AND METHODS
BRPI0922452A2 (pt) * 2008-12-19 2015-12-15 Leo Pharma As composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos.
CA2763900A1 (en) 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2014009425A1 (en) * 2012-07-12 2014-01-16 Chiesi Farmaceutici S.P.A. Inhibition of enzymes
KR102120190B1 (ko) * 2012-09-14 2020-06-08 다우 아그로사이언시즈 엘엘씨 4-아미노-2,5-디메톡시피리미딘으로부터의 2-아미노-5,8-디메톡시[1,2,4]트리아졸로[1,5-c]피리미딘의 개선된 제조 방법
SG11201601707PA (en) 2013-09-05 2016-04-28 Hoffmann La Roche Triazolopyridine compounds, compositions and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE287262C (enExample) *
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives

Also Published As

Publication number Publication date
US6693116B2 (en) 2004-02-17
CA2462801A1 (en) 2003-04-17
KR100604407B1 (ko) 2006-07-25
DE60214408T2 (de) 2007-03-08
MXPA04003278A (es) 2004-07-23
EP1436292B1 (en) 2006-08-30
ES2269772T3 (es) 2007-04-01
BR0213177A (pt) 2004-09-14
US20030134873A1 (en) 2003-07-17
AU2002338827B2 (en) 2007-09-06
CN1564821A (zh) 2005-01-12
KR20040044196A (ko) 2004-05-27
AR036735A1 (es) 2004-09-29
EP1436292A1 (en) 2004-07-14
RU2298009C2 (ru) 2007-04-27
JP4101756B2 (ja) 2008-06-18
JP2005508954A (ja) 2005-04-07
DE60214408D1 (de) 2006-10-12
RU2004114277A (ru) 2006-01-10
CN1254475C (zh) 2006-05-03
PL370565A1 (en) 2005-05-30
WO2003031445A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
DE60218340D1 (de) 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
DE60023167T2 (de) Pyrazol-derivate als cannabinoidrezeptor-antagonisten
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
ATE328871T1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
ATE293618T1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
ATE288898T1 (de) Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
ATE309245T1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3- d)pyrimidin-derivate
DE50210707D1 (de) Substituierte 2-pyridin-cyclohexan-1,4-diaminderivate
DE60331444D1 (de) 1h-1,2,4- triazol-3- carboxamid derivate als cannabinoid-cb1 receptor liganden
PT1381363E (pt) Derivados de imidazo-(1,2-a)-piridina como antagonistas mglur5
DE60209251D1 (de) Adenosine a2a receptor antagonisten
DK1416935T3 (da) 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
ATE360632T1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DE60206652D1 (de) Benzothiazolderivate als adenosin-rezeptor-liganden
DE60133931D1 (de) Kondensierte purinderivate als a1-adenosinrezeptorantagonisten
DE60317684D1 (de) SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
ATE338043T1 (de) 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
DE50008020D1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
MA27094A1 (fr) Derives triazolo-quinoline utiles en tant que ligands recepteurs d'adenosine.
ATE244716T1 (de) Neue n-triazolylmethyl-piperazinderivate als neurokininrezeptor-antagonisten
DE60106974D1 (de) Aminotriazolopyridinderivate als adenosinrezeptorliganden
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1436292

Country of ref document: EP

REN Ceased due to non-payment of the annual fee